24/7 Wall Street
19 Nov 2026, 17:47 UTC · 57m ago
3 Big Pharma Dividend Stocks Built for Retirement Income
Impact · against what's priced in
The article provides a bearish update for Bristol Myers Squibb due to the immediate impact of Eliquis losing exclusivity in Europe. Novartis and Sanofi remain stable as their dividend safety and historical payout records are well-supported by current cash flows.
- BMY−0.50
No priced-in read yet
- In context
The immediate loss of Eliquis exclusivity in Europe this quarter creates an urgent pressure on the $1.29 billion quarterly dividend cost, compounding the expected $1.5 billion to $2 billion revenue drop next year.
Read from the article alone





